1924P Diagnostic demographics of radioiodine-refractory differentiated thyroid cancer (RR-DTC) and usage patterns of local and systemic therapies (ERUDIT study)

Abstract

proteinuria (27.3%), stomatitis (11.4%). Nine (20.5%) pts required treatment discontinuation and reasons were due to death, PD and AE in 5 (11.4%), 2 (4.5%) and 2 (4.5%) pts, respectively. Five deaths occurred. Dose reductions to 20, 18, 14 and 10 mg were in 10 (22.7%), 3 (6.7%), 7 (15.9%) and 7 (15.9%) pts, respectively; 16 (36.4%) pts did not require dose reduction.Conclusions: 61,4 % ORR shows good efficacy of lenvatinib in population of pts with poor performance status (ECOG 1-2).Legal entity responsible for the study: The authors.